Kast WM - Search Results

1

Therapeutic vaccination for HPV induced cervical cancers.

Brinkman JA, Hughes SH, Stone P, Caffrey AS, Muderspach LI, Roman LD, Weber JS, Kast WM. Brinkman JA, et al. Among authors: kast wm. Dis Markers. 2007;23(4):337-52. doi: 10.1155/2007/245146. Dis Markers. 2007. PMID: 17627067 Free PMC article. Review.

2

A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.

Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J. Muderspach L, et al. Among authors: kast wm. Clin Cancer Res. 2000 Sep;6(9):3406-16. Clin Cancer Res. 2000. PMID: 10999722 Clinical Trial.

3

Cervical cancer vaccines: recent advances in HPV research.

Eiben GL, da Silva DM, Fausch SC, Le Poole IC, Nishimura MI, Kast WM. Eiben GL, et al. Among authors: kast wm. Viral Immunol. 2003;16(2):111-21. doi: 10.1089/088282403322017866. Viral Immunol. 2003. PMID: 12828864 Review.

4

Peptide-based vaccines for cancer immunotherapy.

Brinkman JA, Fausch SC, Weber JS, Kast WM. Brinkman JA, et al. Among authors: kast wm. Expert Opin Biol Ther. 2004 Feb;4(2):181-98. doi: 10.1517/14712598.4.2.181. Expert Opin Biol Ther. 2004. PMID: 14998777 Review.

5

Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes.

Markiewicz MA, Kast WM. Markiewicz MA, et al. Among authors: kast wm. Cancer Invest. 2004;22(3):417-34. doi: 10.1081/cnv-200029072. Cancer Invest. 2004. PMID: 15493363 Review.

6

Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells.

Fausch SC, Da Silva DM, Kast WM. Fausch SC, et al. Among authors: kast wm. Vaccine. 2005 Feb 25;23(14):1720-9. doi: 10.1016/j.vaccine.2004.09.035. Vaccine. 2005. PMID: 15705478

7

The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management.

Brinkman JA, Caffrey AS, Muderspach LI, Roman LD, Kast WM. Brinkman JA, et al. Among authors: kast wm. Eur J Gynaecol Oncol. 2005;26(2):129-42. Eur J Gynaecol Oncol. 2005. PMID: 15857016 Review.

8

Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant.

Koh YT, Higgins SA, Weber JS, Kast WM. Koh YT, et al. Among authors: kast wm. J Transl Med. 2006 Oct 23;4:42. doi: 10.1186/1479-5876-4-42. J Transl Med. 2006. PMID: 17059610 Free PMC article.

9

The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors.

Brinkman JA, Xu X, Kast WM. Brinkman JA, et al. Among authors: kast wm. Vaccine. 2007 Apr 30;25(17):3437-44. doi: 10.1016/j.vaccine.2006.12.045. Epub 2007 Jan 10. Vaccine. 2007. PMID: 17241713 Free PMC article.

10

Mechanisms used by human papillomaviruses to escape the host immune response.

Kanodia S, Fahey LM, Kast WM. Kanodia S, et al. Among authors: kast wm. Curr Cancer Drug Targets. 2007 Feb;7(1):79-89. doi: 10.2174/156800907780006869. Curr Cancer Drug Targets. 2007. PMID: 17305480 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

274 results

Search Page